FDA APPROVES EMSAM DEPRESSION PATCH
Bristol-Myers Squibb and Somerset have been given FDA approval to sell Emsam, the first transdermal patch for depression.
The Emsam system consists of a monoamine oxidase inhibitor coupled with a transdermal patch. The FDA approval was supported by two double-blind, placebo-controlled studies. In one trial a six-week course of Emsam was more effective than placebo in relieving symptoms in adult patients with major depressive disorder.